Jump to content

Drilldown: Medicines

Choose a table:


Medicines > generic: None & classes : Dissociative or low-trapping)

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
REL-1017 / esmethadone (investigational; not yet FDA-approved as of mid-2024) (1) · Spravato (1)
classes: (Click arrow to add another value)
mechanism:
None (2)
uses:
Investigational for major depressive disorder; trials underway (phase 3 mixed results) (1) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)
starting dose:
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1) · Trials use 25 mg or 50 mg PO daily (1)
preparations:
28 mg/device (each dose uses 2 devices) (1) · Investigational oral capsule (1)
fda max:
84 mg per session (1) · Not yet approved (1)
routes:
Intranasal (under direct medical supervision) (1) · Oral (1)
onset:
Rapid (within 1 week in trials) (1) · Within hours of first administration (1)
duration:
Acute effect ~24 hours; cumulative effect builds with repeated dosing (1) · Daily dosing (1)
halflife:
Not formally established (1) · ~7-12 hours (1)
bioavailability:
Oral bioavailability suitable for daily dosing (1) · ~48% intranasal (1)
pregnancy:
Avoid; may cause fetal harm (1) · Investigational (1)
legal:
Investigational (1) · Rx, Schedule III (US). REMS program required. (1)

Showing below up to 2 results in range #1 to #2.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"